Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency

被引：20

作者：

Jeremias, A ^{[1
]}

Bhatt, DL ^{[1
]}

Chew, DP ^{[1
]}

Ziada, KM ^{[1
]}

Albirini, A ^{[1
]}

Brener, SJ ^{[1
]}

Lincoff, M ^{[1
]}

Topol, EJ ^{[1
]}

Ellis, SG ^{[1
]}

机构：

[1] Cleveland Clin Fdn, Dept Cardiovasc Med, Sones Cardiac Catheterizat Lab, Cleveland, OH 44195 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2002年 / 89卷 / 10期

关键词：

D O I：

10.1016/S0002-9149(02)02308-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of this study was to evaluate bleeding risk and to assess the impact of abciximab therapy on outcome in patients with chronic renal insufficiency who underwent percutaneous coronary intervention (PCI). Despite a slightly higher decrease in hemoglobin after catheterization in the abciximab group. there was only a moderate and statistically insignificant increase in major bleeding complications and need for red blood cell transfusions, demonstrating the safety of abciximab during PCI.

引用

页码：1209 / +

页数：4

共 12 条

[1] COMPLICATIONS AND LONG-TERM OUTCOME AFTER PERCUTANEOUS CORONARY ANGIOPLASTY IN CHRONIC-HEMODIALYSIS PATIENTS [J].

AHMED, WH ;

SHUBROOKS, SJ ;

GIBSON, CM ;

BAIM, DS ;

BITTL, JA .

AMERICAN HEART JOURNAL, 1994, 128 (02) :252-255

[2]

Best PJM, 2001, J AM COLL CARDIOL, V37, p4A

[3] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[4]

HARKER LA, 1987, AM J CARDIOL, V60, P20

[5] SHORT-TERM AND LONG-TERM OUTCOME OF PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY IN CHRONIC DIALYSIS PATIENTS [J].

KAHN, JK ;

RUTHERFORD, BD ;

MCCONAHAY, DR ;

JOHNSON, WL ;

GIORGI, LV ;

HARTZLER, GO .

AMERICAN HEART JOURNAL, 1990, 119 (03) :484-489

[6]

*MED EC CO, 1999, PHYS DESK REF

[7] A COMPARISON OF CORONARY ANGIOPLASTY AND CORONARY-ARTERY BYPASS-GRAFTING OUTCOMES IN CHRONIC DIALYSIS PATIENTS [J].

RINEHART, AL ;

HERZOG, CA ;

COLLINS, AJ ;

FLACK, JM ;

MA, JZ ;

OPSAHL, JA .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 25 (02) :281-290

[8]

Rubenstein MH, 2000, CIRCULATION, V102, P2966

[9]

Tcheng JE, 1997, LANCET, V349, P1422

[10] Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure [J].

Ting, HH ;

Tahirkheli, NK ;

Berger, PB ;

McCarthy, JT ;

Timimi, FK ;

Mathew, V ;

Rihal, CS ;

Hasdai, D ;

Holmes, DR .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (05) :630-633

← 1 2 →